Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)
NCT00956787
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
25
Enrollment
INDUSTRY
Sponsor class
Conditions
Myelodysplastic Syndrome
Interventions
DRUG:
AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)
Sponsor
Arno Therapeutics